Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

TY - JOUR

T1 - Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years

T2 - 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

AU - McNeil, Shelly

N1 - Publisher Copyright: © 2016 Elsevier Ltd

PY - 2016/10/1

Y1 - 2016/10/1

UR - http://www.scopus.com/inward/record.url?scp=84977668330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977668330&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(16)30120-7

DO - 10.1016/S1473-3099(16)30120-7

M3 - Article

C2 - 27373900

AN - SCOPUS:84977668330

SN - 1473-3099

VL - 16

SP - 1154

EP - 1168

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 10

ER -